Trialbee Honey™ Adds New Features
Latest enhancements will optimize Omnichannel capabilities for ROI reporting.
Trialbee has enhanced its Omnichannel recruitment strategy by adding features for transparency into performance across all channels, sources, and recruitment partners.
Available in the Trialbee Honey™ platform, these vendor-agnostic insights provide real-time ROI data, With Honey Omnichannel, customers can:
- Understand the current status, progress, and trajectory of their enrollment milestones.
- Objectively evaluate partner performance including third-party recruitment providers, CROs, patient advocacy groups, and more.
- Dive deep into the relative value of specific social channels (e.g., Facebook, Instagram, TikTok), digital mediums (email, social, programmatic), and individual campaigns by each referrer in their recruitment ecosystem.
By aggregating and analyzing all referrer channels into a single funnel with visual dashboards and insightful analytics, Trialbee Honey™ enables enrollment outcomes through stronger candidate sourcing.
Reference
Trialbee Honey™ Adds New Features to Optimize Omnichannel Capabilities for ROI Reporting Across All Patient Recruitment Sources and Vendors. (2023, May 17). Cision PRWeb.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
